#125129
#125130
Re: Farmas USA
#125132
Re: Farmas USA
KPTI
En legible: resultados estadísticamente significativos. Primer tratamiento oral para liposarcoma. No está descontado.
https://www.stocktitan.net/news/KPTI/karyopharm-announces-phase-3-seal-study-meets-primary-endpoint-with-yx6odeyvwdn0.html
En legible: resultados estadísticamente significativos. Primer tratamiento oral para liposarcoma. No está descontado.
https://www.stocktitan.net/news/KPTI/karyopharm-announces-phase-3-seal-study-meets-primary-endpoint-with-yx6odeyvwdn0.html
#125133
Re: Farmas USA
#125134
Re: Farmas USA
KpTI
Trimestrales
Third Quarter 2020 XPOVIO Net Product Sales of $21.3 Million; Quarterly Sales Continue Strong Momentum, Increasing Approximately 15% Compared to the Second Quarter of 2020 --
21,4 esperaban analistas según IB. -0,73 vs. -0,72 EPS esperado. Edito: según SA supera en ambas
Trimestrales
Third Quarter 2020 XPOVIO Net Product Sales of $21.3 Million; Quarterly Sales Continue Strong Momentum, Increasing Approximately 15% Compared to the Second Quarter of 2020 --
21,4 esperaban analistas según IB. -0,73 vs. -0,72 EPS esperado. Edito: según SA supera en ambas
Karyopharm Therapeutics EPS beats by $0.01, beats on revenue
#125135
Re: Farmas USA
Buenas noticias para $KPTI Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma
+23% AH
- Karyopharm Therapeutics (NASDAQ:KPTI)announces positive results from a Phase 3 clinical trial, SEAL, evaluating Xpovio (selinexor) in patients with advanced unresectable dedifferentiated liposarcoma, a high-grade subtype of the rare form of soft tissue cancer that begins in fat cells.
- The study met the primary endpoint of progression-free survival (PFS) with 30% less risk of cancer progression or death (hazard ratio = 0.70).
- No new safety signals were observed.
- Detailed results will be virtually presented at the Connective Tissue Oncology Society Annual Meeting on Friday, November 20.
- The FDA approved Xpovio in July 2019 for multiple myeloma and in June of this year for diffuse large B-cell lymphoma.
#125136
